Comparative Pharmacology
Head-to-head clinical analysis: IBU TAB 200 versus INDO LEMMON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBU TAB 200 versus INDO LEMMON.
IBU-TAB 200 vs INDO-LEMMON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes, reducing inflammation, pain, and fever.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.
Oral: 25-50 mg 2-3 times daily. Maximum daily dose: 200 mg.
None Documented
None Documented
2-4 hours (terminal half-life). Short half-life requires frequent dosing for sustained analgesic/antipyretic effect.
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Renal: 90% as metabolites (glucuronides, hydroxylated derivatives), <10% unchanged. Fecal: <5%.
Renal excretion of unchanged drug and metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for approximately 40%.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)